Cancer Immunity (13 August 2007) Vol. 7, p. 12
نویسندگان
چکیده
Significant work in animal models combined with compelling studies in human patients together have begun to provide a higher resolution picture of how the immune system regulates cancer development. Currently, this immune system-tumor interaction is represented by the concept of cancer immunoediting, which emphasizes that immunity may subserve either classical cancer immunosurveillance functions or promote the eventual outgrowth of immunoevasive cancer cells. One important line of evidence supporting an immunosurveillance process in humans has been the finding that the presence of distinct profiles of TILs may be correlated with improved clinical outcomes in a subset of human cancers. However, the contribution of TILs to the natural history of gliomas is less clear. Moreover, understanding the relationship between TILs and cancers of the brain is particularly challenging because our understanding of how immune responses develop in the central nervous systems is still evolving. In this review, we will first provide an overview of three important themes in the central nervous system anti-tumor immunity−i.e., antigen expression, how antigen may be presented, and lymphocyte trafficking−and subsequently discuss the extant work on TILs in glioma.
منابع مشابه
Cancer Immunity (28 August 2008) Vol. 8, p. 13
1First Department of Medicine, Hokkaido University School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan 2Department of Immunology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan 3Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 06...
متن کاملCancer Immunity (17 August 2007) Vol. 7, p. 14
1027. 31. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM. A phase I multiple dose, dose esca-lation study of cG250 monoclonal antibody in patients withadvanced renal cell carcinoma. Cancer Immun 2007; 7: 13. URL: http://www.cancerimmunity.org/v7p13/070713.htm 32. Bevan P, Mala C, Kindler ...
متن کاملCancer Immunity (22 October 2007) Vol. 7, p. 17
1Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom 2Dept. of Histopathology, Addenbrooke's NHS Trust, Cambridge, United Kingdom 3Dep. of Histopathology, City Hospital, Nottingham, NG5 1PB, United Kingdom 4Dep. of Pathology, Iran University of Medical Sciences, Tehran, Iran *T...
متن کاملCancer Immunity (5 March 2007) Vol. 7, p. 5
XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a, b, c and d, XAGE-1b mRNA was dominantly expressed in cancer. In this study, we generated a XAGE-1b mAb, USO9-13. The B cell epitope recognized by the USO9-13 mAb was in the C-terminal region of the XAGE-1b protein and is also recognized by sera fro...
متن کاملCancer Immunity (24 August 2007) Vol. 7, p. 15
Besides their variable presence in fetal and adult germ cells, CT antigens have occasionally been detected in placental tissue. However, these data are scarce and solely based on mRNA analyses; nothing is known about their presence at the protein level. Here, we analyzed the expression of various CT antigens in placental tissues from gestational age week 5 to week 42 using monoclonal antibodies...
متن کامل